Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bortezomib together with temozolomide after surgery may kill any tumor cells that remain after surgery. This phase II trial is studying how well giving bortezomib before surgery followed by giving bortezomib together with temozolomide after surgery works in treating patients with recurrent malignant glioma.
Key facts
- Study ID
- NCT00990652
- Run by
- Northwestern University
- People needed
- 10
- Starts
- 2009-05-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2014-01-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed malignant glioma, including any of the following subtypes:
- Glioblastoma multiforme
- Gliosarcoma
- Anaplastic astrocytoma
- Anaplastic oligodendroglioma
- Anaplastic mixed oligoastrocytoma
- Malignant astrocytoma not otherwise specified
- Must show unequivocal evidence of tumor recurrence or progression by MRI or CT scan with contrast
- Candidate for surgery AND requires surgery
- Evaluable or measurable disease following resection of recurrent tumor is not required
- Failed prior standard radiotherapy and temozolomide
- Patients who have undergone stereotactic radiosurgery must have confirmation of true progressive disease (rather than radiation necrosis) by PET scan, magnetic resonance spectroscopy (MRS), or magnetic resonance perfusion (MRP) prior to surgery
- Patients with lower-grade gliomas that have undergone radiographic malignant transformation allowed provided they failed radiotherapy (with or without temozolomide) and require surgery
- Life expectancy > 12 weeks
You may not qualify if…
- Not pregnant or nursing
- Negative pregnancy test
- No other medical issues (e.g., bleeding, infection, HIV, or serious medical or psychiatric illness) that would preclude study therapy
- Myocardial infarction within the past 6 months
- No other active cancer(s) except non-melanoma skin cancer or carcinoma in situ of the cervix, unless in complete remission and off of all therapy for that cancer for ≥ 3 years
- No hypersensitivity to bortezomib, boron, or mannitol
- More than 4 weeks since prior radiotherapy
- At least 4 weeks since prior cytotoxic therapy (6 weeks for nitrosoureas)
- At least 3 weeks since prior investigational drugs
- At least 2 weeks since prior enzyme-inducing anticonvulsants
- Concurrent non-enzyme-inducing anticonvulsants allowed
- No other concurrent standard or investigational anticancer treatment
Where it is running
- Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.